Goldman Sachs Group Inc. Cuts Stock Position in Gyre Therapeutics, Inc. $GYRE

Goldman Sachs Group Inc. lessened its stake in Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 38.8% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 16,147 shares of the company’s stock after selling 10,239 shares during the quarter. Goldman Sachs Group Inc.’s holdings in Gyre Therapeutics were worth $125,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its stake in Gyre Therapeutics by 40.4% during the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock worth $84,000 after purchasing an additional 1,996 shares during the last quarter. Advantage Alpha Capital Partners LP boosted its position in shares of Gyre Therapeutics by 54.0% during the 1st quarter. Advantage Alpha Capital Partners LP now owns 13,663 shares of the company’s stock valued at $105,000 after acquiring an additional 4,790 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Gyre Therapeutics by 18.7% in the first quarter. Bank of New York Mellon Corp now owns 16,492 shares of the company’s stock valued at $127,000 after buying an additional 2,596 shares during the last quarter. GAMMA Investing LLC lifted its position in Gyre Therapeutics by 15,083.3% in the first quarter. GAMMA Investing LLC now owns 1,822 shares of the company’s stock valued at $140,000 after buying an additional 1,810 shares during the last quarter. Finally, American Century Companies Inc. acquired a new position in Gyre Therapeutics in the first quarter valued at about $184,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright initiated coverage on shares of Gyre Therapeutics in a research report on Tuesday, August 26th. They issued a “buy” rating and a $18.00 target price on the stock. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Gyre Therapeutics has a consensus rating of “Buy” and a consensus price target of $18.00.

Gyre Therapeutics Stock Performance

GYRE stock opened at $7.50 on Tuesday. The firm has a market capitalization of $722.33 million, a price-to-earnings ratio of 750.75 and a beta of 1.86. Gyre Therapeutics, Inc. has a fifty-two week low of $6.11 and a fifty-two week high of $19.00. The company’s 50 day moving average price is $7.60 and its 200 day moving average price is $8.26.

Gyre Therapeutics (NASDAQ:GYRE) last announced its quarterly earnings results on Monday, August 11th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $26.77 million during the quarter, compared to analysts’ expectations of $30.80 million. Gyre Therapeutics had a net margin of 4.08% and a return on equity of 7.67%.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.